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Objectives. The present study was designed to compare the 
secretion patterns of two cardiac hormones--A-type (atrial) and 
B-type (brain) natriuretic peptides--from the ventricles in pa- 
tients with old myocardial infarction. 
Background. Plasma levels of these two natriuretic peptides are 
increased, and their secretion from the ventricles is augmented, in 
patients with congestive heart failure. 
Methods. We measured the plasma levels of these two types of 
natriuretic peptides at the aortic root and the anterior interven- 
tricular vein in 42 patients with old myocardial infarction (ante- 
rior in 22 and inferior in 20) and 18 control subjects. 
Results. The difference between the plasma levels of both A- and 
B-type natriuretic peptide in the anterior interventricular vein 
and aortic root was significantly greater in the groups with 
anterior and inferior infarction than in the control group (A-type 
[mean -+ SD] 380 -+ 290 and 247 -+ 205 pg/ml in the infarction 
groups vs. 11 - 14 pg/ml; B-type 497 -- 445 and 75 + 73 pg/ml vs. 
23 -+ 16 pg/ml, respectively). The difference between the plasma 
levels of each peptide at the anterior interventricular vein and 
aortic root had a significant negative linear correlation with left 
ventricular ejection fraction in both groups with infarction. The 
slope of the regression line of the arteriovenous difference of 
B-type natriuretic peptide at the anterior interventricular vein 
was significantly steeper in the anterior than in the inferior 
infarction group (left ventricular ejection fraction -12.801 vs. 
-1.891, p < 0.01). 
Conclusions. These results indicate that 1) the secretion of A- 
and B-type natriuretic peptide from the left ventricle increases in 
proportion to the severity of left ventricular dysfunction, and 
2) secretion of B-type natriuretic peptide is much greater from the 
infarct than from the noninfarct region, suggesting that the 
regional ventricular wall stretch caused by infarction strongly 
stimulates ecretion of B-type natriuretic peptide. 
(JAm Coil Cardiol 1995;25:1105-10) 
A-type (atrial) natriuretic peptide is a hormone with a wide 
range of biologic effects, including natriuresis, diuresis, vaso- 
dilation and inhibition of the renin-angiotensin-aldosterone 
and sympathetic nervous systems (1-6). A-type natriuretic 
peptide is mainly synthesized in and secreted from the atria in 
adult mammals and its plasma levels are increased in patients 
with congestive heart failure (1-5,7-10). We and others (11- 
15) have shown that A-type natriuretic peptide is also synthe- 
sized in and secreted from the ventricles in patients with 
congestive heart failure, and the amount secreted has a 
positive correlation with left ventricular dysfunction i  dilated 
cardiomyopathy (11-15). 
B-type (brain) natriuretic peptide, first isolated from a 
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porcine brain (16) and subsequently from human hearts (17), 
forms a peptide family with A-type natriuretic peptide and may 
be involved in the regulation of blood pressure and fluid 
volume. The plasma levels of B-type natriuretic peptide are 
markedly increased in patients with congestive heart failure 
(17-20) and in those with acute myocardial infarction (21,22). 
B-type natriuretic peptide is reported to be mainly synthesized 
in and secreted from the ventricles (17,23). However, the 
precise mechanisms of the secretion of A-type and B-type 
natriuretic peptides in living humans is not known. 
We (7,13,15) have shown that A-type natriuretic peptide is 
released into the general circulation mainly by way of the 
coronary sinus. Because the anterior interventricular vein 
drains blood mainly from the left anterior ventricle (24-26), 
the difference between plasma levels of A- and B-type natri- 
uretic peptide in the anterior interventricular vein and the 
aortic root reflects the amount of the peptides released mainly 
from the anterior ventricle. 
The present study was designed to examine the sites and 
mechanism of the secretion of A- and B-type natriuretic 
peptides from the anterior ventricle by sampling blood for 
these peptides from the aortic root, anterior interventricular 
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Table 1. Clinical Characteristics of the Patients With Old 
Myocardial Infarction 
Anterior MI Inferior MI 
(n = 22) (n = 20) 
Age (yr) (mean; range) 64; 46-80 64; 45-75 
M/F ratio 17/5 17/3 
NYHA class 
I/II 7/7 13/3 
Ill/IV 6/2 4/0 
Drug therapy 
Aspirin 22 19 
Calcium channel b ockers 16 15 
Alone 2 3 
With nitrates 6 9 
With nitrates, beta-blockers 3 1 
With nitrates, ACEI 3 2 
With nitrates, ACEI, diuretic drugs 2 0 
Nitrates without calcium channel 3 0 
blockers 
Alone l 0 
With ACEI 2 0 
Unless otherwise indicated, all data are expressed as number of patients. 
ACEI = angiotensin-converting e zyme inhibitor; Anterior MI = patients with 
old anterior myocardial infarction; F = female; Inferior MI - patients with old 
inferior myocardial infarction; M = male; NYHA class = New York Heart 
Association functional ,:lass. 
vein and coronary sinus in patients with old myocardial infarc- 
tion and control subjects. 
Methods 
Patients. Three groups of patients were studied: patients 
with anterior or inferior old myocardial infarction and a 
control group. 
Patients with old myocardial infarction. The clinical charac- 
teristics of the 42 patients with old myocardial infarction are 
shown in Table 1. Diagnostic ardiac catheterization, per- 
formed -> 1 month after the onset of infarction (mean 65 days, 
range 31 to 375), revealed that the infarct-related artery was 
the left anterior descending coronary artery in the patients 
with anterior infarction and the right coronary artery in those 
with inferior infarction. The infarct region was also assessed by 
left ventriculography and thalium-201 myocardial scintigraphy. 
In all patients, angiotensin-converting e zyme inhibitors 
were withdrawn 3 to 5 days before the study; all other drugs 
were withheld ->1 day before the study. 
Controlgroup. The control group comprised 18 patients (11 
men and 7 women with a mean age of 62 years [range 46 to 74]) 
in whom diagnostic ardiac atheterization including coronary 
angiography and left ventriculography was performed and 
insertion of a catheter into the anterior interventricular vein 
was possible. Nine control patients had atypical chest pain 
syndrome with normal coronary arteriographic findings and 
nine had stable angina pectoris. None had old myocardial 
infarction, cardiac hypertrophy orother heart muscle disease, 
renal impairment (serum creatinine l vel >2.0 mg/dl), hyper- 
tension or ventricular hypertrophy. All drugs were withheld -> 1 
week before the study. 
Ethical guidelines. This study protocol was in an agreement 
with the guideline by the ethics committee at our institution, 
and written informed consent was obtained from each patient. 
Cardiac catheterization. Cardiac catheterization was per- 
formed in the morning with patients in the fasting state. 
Cardiac output was determined by the thermodilution tech- 
nique in triplicate. After completion of right heart catheteriza- 
tion, a 6F Goodale-Lubin catheter was placed in the coronary 
sinus by way of the brachial vein. The catheter was then 
advanced to the anterior interventricular vein under fluoros- 
copy by using a guide wire, as previously reported (1335). The 
position of the catheter tip in the anterior interventricular vein 
was confirmed by injection of contrast material. A Sones 
catheter was placed at the aortic root by way of a right brachial 
artery. Sampling of blood for A- and B-type natriuretic peptide 
levels was performed simultaneously from the aortic root, the 
anterior interventricular vein and the coronary sinus; special 
care was taken to draw blood samples lowly from the anterior 
interventricular vein. Coronary arteriography and left ventricu- 
lography were performed in each patient. 
Hormonal analysis. All blood samples were withdrawn 
into plastic syringes and transferred to chilled siliconized 
disposable tubes with aprotinin (1,000 kallikrein inactivator 
units/ml) (Ohkura Pharmaceutical, Kyoto, Japan) and ethyl- 
enediaminetetraacetic acid (1 mg/ml), then immediately 
placed on ice and centrifuged at4°C. An aliquot of plasma was 
immediately frozen at -80°C and thawed only once at the time 
of assay within 1 week. 
Plasma A-type natriuretic peptide concentration was mea- 
sured by a specific immunoradiometric assay for alpha-human 
A-type natriuretic peptide (Shionoria ANP kit, Osaka, Japan) 
as previously reported (15). The minimal detectable quantity 
of alpha-human A-type natriuretie peptide is 5 pg/ml. The 
intraassay and interassay coefficients of variation were 4.7% 
and 5.8%, respectively. The cross-reactivity with human B-type 
natriuretic peptide was <0.001% on a molar basis. 
Plasma B-type natriuretic peptide concentration was mea- 
sured with a new and specific immunoradiometric assay for 
human B-type natriuretie peptide as previously reported (15). 
The minimal detectable quantity of human B-type natriuretic 
peptide is 2 pg/ml. The intraassay and interassay coefficients 
of variation were 5.3% and 5.9%, respectively. The cross- 
reactivity with alpha-human A-type natriuretic peptide was 
<0.001% on a molar basis. 
Statistical analysis. All values are expressed as mean value 
± SD. Statistical significance was defined as a p value <0.05. 
Variables were compared between two groups by unpaired t 
test. Hormonal levels at the aortic root, anterior interventric- 
ular vein and coronary sinus within the group were compared 
by using one-way analysis of variance (ANOVA) with repeated 
measurements followed by the Fisher test. Stepwise regression 
analysis was undertaken to determine which hemodynamic 
variable was most closely correlated with the plasma levels of 
A- and B-type natriuretic peptide. The correlation of these 
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Table 2. Hemodynamic Data in the Control Group and Groups 
With Old Anterior and Inferior Myocardial Infarction 
Anterior Inferior 
Control MI MI 
(n = 18) (n = 22) (n = 20) 
HR (beats/min) 73 + 12 74 + 12 70 _+ 11 
AOP (mm Hg) 95 _+ 13 100 _+ 13 96 -+ 14 
RAP (ram Hg) 2 +- 2 4 + 2* 4 -+ 2"~ 
PCWP (ram Hg) 5 _+ 2 14 _+ 9":~ 10 + 5t 
CI (liters/rain per m e) 2.9 _+ 0.6 2.6 _+ 0.7 2.7 +_ 0.3 
LVEF (%) 78 +_ 4 39 _+ 18"§ 50 + 13' 
*p < 0.01 versus the control group, lp  < 0.05 versus the control group. 
:~p < 0.05 versus the old inferior myocardial infarction group. §p < 0.01 versus 
the old inferior myocardial infarction group. Values are expressed as mean value 
_+ SD. Anterior MI - old anterior myocardial infarction group; AOP - aortic 
mean pressure; CI = cardiac index; Control - control group; HR = heart rate; 
Inferior MI = old inferior myocardial infarction group; LVEF = left ventricular 
ejection fraction; PCWP = pulmonary capillary wedge pressure; RAP = right 
atrial pressure. 
plasma levels with hemodynamic variables was examined by 
using linear regression analysis. The slopes of the linear 
regression lines were compared between the anterior and the 
inferior infarction groups by analysis of covariance (27). 
Results 
Hemodynamic variables. Table 2 shows the hemodynamic 
variables in the two groups with myocardial infarction and the 
control group. There were no significant differences in heart 
rate, aortic mean pressure or cardiac index among the three 
groups. Pulmonary capillary wedge and right atrial pressures 
were significantly higher and the left ventricular ejection 
fraction was significantly lower in the two infarction groups 
than in the control group. Pulmonary capillary wedge pressure 
was significantly higher and the left ventricular ejection frac- 
tion was significantly ower in the anterior than in the inferior 
infarction group. 
Plasma A- and B-type natriuretic peptide levels at three 
sampling sites. The plasma A-type natriuretic peptide levels 
at the three sampling sites were significantly higher in the 
groups with anterior (p < 0.001) and inferior (p < 0.001) 
infarction than in the control group (aortic root 174 _+ 248 and 
97 +_ 76 pg/ml vs. 35 _+ 27 pg/ml; anterior interventricular vein 
554 + 468 and 344 _+ 234 pg/ml vs. 46 _+ 26 pg/ml; coronary 
sinus 779 + 508 and 727 + 187 pg/ml vs. 278 - 187 pg/ml) (Fig. 
1, upper panel). The plasma A-type natriuretic peptide levels 
were significantly higher (p < 0.01) in the anterior group than 
in the inferior group at all three sampling sites. 
The plasma B-type natriuretic peptide levels at all three 
sampling sites were significantly higher in the anterior (p < 
0.001) and inferior (p < 0.01) infarction groups than in the 
control group (aortic root 340 _+ 472 and 125 + 81 pg/ml vs. 
12 + 8 pg/ml; anterior interventricular vein 853 _+ 817 and 
198 + 125 pg/ml vs. 35 + 21 pg/ml; coronary sinus 806 _+ 826 
and 331 + 227 pg/ml vs. 34 _+ 17 pg/ml) (Fig. 1, lower panel). 
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Figure 1. Plasma levels of A-type (ANP) and B-type (BNP) natriuretic 
peptide at three sampling sites in the groups with old anterior 
myocardial infarction (Anterior MI) and old inferior myocardial 
infarction (Inferior MI) and the control group (Control). The mean 
value +_ SD for each plasma level at each sampling site is also shown 
(large symbols and bars). AIV = anterior interventricular vein; CS: 
coronary sinus. 
The plasma B-type natriuretic peptide levels at all three 
sampling sites were significantly higher (p < 0.01) in the 
anterior than in the inferior infarction group. 
Figure 2 shows chematically the changes in both plasma A- 
and B-type natriuretic peptide levels from the aortic root to the 
anterior interventricular vein and coronary sinus in the three 
groups. In the control group (Fig. 2A), the plasma A-type 
natriuretic peptide level did not differ between the aortic root 
and anterior interventricular vein, but increased significantly 
(p < 0.001) from the anterior interventricular vein to the 
coronary sinus. In contrast, the plasma B-type natriuretic 
peptide level in the control group increased significantly (p < 
0.001) from the aortic root to the anterior interventricular vein 
(p < 0.001) but did not differ between the anterior interven- 
tricular vein and the coronary sinus. 
In the anterior myocardial infarction group (Fig. 2B), the 
plasma A-type natriuretic peptide level increased significantly 
between the aortic root and anterior interventricular vein (p < 
0.001) and between the anterior interventricular vein and 
coronary sinus (p < 0.01). The plasma B-type natriuretic 
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Figure 2. Schematic presentation f the changes inthe plasma levels 
of A-type (ANP) and B-type (BNP) natriuretic peptides at the three 
sampling sites in the control group (A) and the groups with old anterior 
(B) and inferior (C) myocardial infarction. Values are expressed as
mean value _+ SD in pg/ml. AIV - anterior interventricular vein; 
Ao = aortic root; CS = coronary sinus. 
peptide level in this group increased significantly (p < 0.001) 
between the aortic root and anterior interventricular vein, but 
did not differ between the anterior interventricular vein and 
coronary sinus. 
In the inferior infarction group (Fig. 2C), the A-type 
natriuretic peptide level increased significantly (p < 0.001) 
between the aortic root and anterior interventricular vein and 
also between the anterior interventricular vein and coronary 
sinus. The plasma B-type natriuretic peptide level in this group 
increased significantly between the aortic root and anterior 
interventricular vein (p < 0.01) and between the anterior 
interventricular vein and coronary sinus (p < 0.001). 
The difference between the plasma levels of A-type natri- 
uretic peptide in the anterior interventricular vein and aortic 
root was significantly greater in the anterior and inferior 
infarction groups than in the control group (380 _+ 290 and 
247 _+ 205 pg/ml vs. 11 _+ 14 pg/ml, p < 0.001 and p < 0.001, 
respectively). The difference between these plasma levels in 
the coronary sinus and aortic root was also significantly greater 
in the infarction groups than in the control group (606 _+ 348 
and 622 _+ 345 pg/ml vs. 244 + 175 pg/ml, p < 0.001 and p < 
0.001, respectively). 
The difference between the plasma levels of B-type natri- 
uretic peptide in the anterior interventricular vein and aortic 
root was similarly significantly greater in the anterior and 
inferior infarction groups than in the control group (497 ± 445 
and 75 + 73 pg/ml vs. 23 + 16 pg/ml, p < 0.001 and p < 0.01, 
respectively). The difference between these plasma levels in 
the coronary sinus and aortic root was also significantly greater 
in the infarction groups than in the control group (470 _+ 412 
and 208 ± 158 pg/ml vs. 23 _+ 15 pg/ml, p < 0.001 and p < 0.01, 
respectively). 
Correlation of the increases in A- and B-type natriuretic 
peptide levels at the anterior interventricular vein with hemo- 
dynamic variables. Stepwise linear regression analysis was 
undertaken to determine which hemodynamic variable was 
most closely correlated with the differences between the 
plasma A- and B-type natriuretic peptide levels in the anterior 
interventricular vein and the aortic root. Ejection fraction was 
found to be most significantly correlated in the anterior 
infarction group (F = 38.8 for A-type; F = 38.4 for B-type 
natriuretic peptide), whereas pulmonary capillary wedge pres- 
sure was most significantly correlated in the inferior infarction 
group (F = 29.1 for A-type; F = 17.2 for B-type). 
The difference between plasma A-type natriuretic peptide 
level in the anterior interventricular vein and aortic root 
showed asignificant positive linear correlation with pulmonary 
capillary wedge pressure (anterior infarction group r = 0.615, 
p < 0.001; inferior infarction group r = 0.669, p < 0.01). It also 
showed a significant negative linear correlation with left ven- 
tricular ejection fraction (anterior infarction group r = -0.711, 
p < 0.001; inferior infarction group r = -0.522, p < 0.001) 
(Fig. 3, upper panel) 
The difference between the plasma B-type natriuretic pep- 
tide level in the anterior interventricular vein and aortic root 
showed asignificant positive linear correlation with pulmonary 
capillary wedge pressure (anterior infarction group r = 0.716, 
p < 0.001; inferior infarction group r = 0.568, p < 0.001. It also 
showed a significant negative linear correlation with left ven- 
tricular ejection fraction (anterior infarction group r = -0.748, 
p < 0.001; inferior infarction group r = -0.568, p < 0.001) 
(Fig. 3, lower panel). 
Comparison of linear regression line slope between the 
anterior and inferior myocardial infarction groups. There 
was no significant difference in the slopes of the regression 
lines of the arteriovenous difference of the plasma A-type 
natriuretic level at the anterior interventricular vein between 
the anterior and inferior infarction groups (pulmonary capil- 
lary wedge pressure 22.929 vs. 27.718; left ventricular ejection 
fraction -8.504 vs. -5.507) (Fig. 3, upper panel). In contrast, 
the slopes of the regression lines of the arteriovenous differ- 
ence of the plasma B-type natriuretic level at the anterior 
interventricular vein were significantly steeper in the anterior 
than in the inferior infarction group (pulmonary capillary 
wedge pressure 38.131 vs. 7.438, p < 0.01; left ventricular 
ejection fraction -12.801 vs. -1.891, p < 0.01) (Fig. 3, lower 
panel). 
Discuss ion  
B-type natriuretic peptide, a cardiac hormone synthesized 
mainly in the ventricles, forms a natriuretic peptide family with 
A-type natriuretic peptide (16-18). We and others (17-20) 
have shown that plasma levels of these two peptides are 
increased in patients with congestive heart failure, There has 
been no systematic study of the secretion of A- and B-type 
natriuretic peptides from the heart of patients with an old 
myocardial infarction. In this study, we measured the plasma 
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Figure 3. Correlation of arteriovenous difference of plasma A-type 
(ANP) and B-type (BNP) natriuretic peptide levels at the anterior 
interventricular vein (AIV) [AANP(AIV-Ao), ABNP(AIV-Ao)] with 
pulmonary capillary wedge pressure (PCWP) and left ventricular 
ejection fraction (LVEF) in patients with old anterior and inferior 
myocardial infarction (MI). There was no significant difference in the 
slopes of the regression li es of the arteriovenous difference of the 
plasma A-type natriuretic peptide levels at the anterior interventricu- 
lar vein between the two infarction groups. The slopes of the regres- 
sion lines of the arteriovcnous difference of the plasma B-type 
natriuretic peptide levels at the anterior interventricular vein were 
significantly steeper in the anterior than in the inferior infarction 
group. Ao = aortic root. 
levels of these peptides at the aortic root, anterior interven- 
tricular vein and coronary sinus in patients with anterior and 
inferior myocardial infarction and control patients. The results 
showed that the plasma levels of both peptides were signifi- 
cantly greater at all three sites in both groups with infarction 
than in the control patients. 
Augmented secretion of A- and B-type natriuretic peptides 
from the ventricle in myocardial infarction. The anterior 
interventricular vein drains the anterior ventricle (24-26). 
The difference between plasma levels of natriuretic peptides 
in the anterior interventricular vein and aortic root thus 
reflects the amount of the peptides ecreted from the anterior 
ventricle. In the control group, plasma A-type natriuretic 
peptide level did not differ significantly between these two 
sampling sites, whereas plasma B-type natriuretic peptide level 
increased significantly from the aortic root to the anterior 
interventricular vein. These findings are consistent with previ- 
ous data (13,15,17). 
In the anterior infarction group, the secretion of A- and 
B-type natriuretic peptides from the anterior ventricle reflects 
the amount of the peptides released from the infarct region, 
whereas in the inferior infarction group it reflects the amount 
released from the noninfarct region. The amount of A- and 
B-type natriuretic peptides secreted from the anterior ventricle 
was significantly higher in both infarction groups than in the 
control group. Thus, secretion of these peptides from the 
ventricle is augmented in both infarct and noninfarct areas in 
patients with myocardial infarction. 
The amount of A- and B-type natriuretic peptides ecreted 
from the anterior ventricle had a significant positive linear 
correlation with pulmonary capillary wedge pressure and a 
significant negative linear correlation with left ventricular 
ejection fraction in both infarction groups. These results 
indicate that increasing deterioration of left ventricular func- 
tion is accompanied by an increased release of both peptides 
from the ventricle not only in the infarct region but also in the 
noninfarct region. The increased wall tension or stretch as a 
consequence of ventricular dilation may stimulate the secre- 
tion of A- and B-type natriuretic peptides from the ventricle. 
Regional stretch as a possible cause of increased secretion 
of B-type natriuretic peptide. To compare the amount of 
B-type natriuretic peptide secreted from the infarct and non- 
infarct regions, we compared the slope of the linear regression 
line of B-type natriuretic peptide secretion from the anterior 
ventricle in the anterior and inferior infarction groups. The 
slope was significantly steeper in the anterior than in the 
inferior infarction group. This finding indicates that the secre- 
tion of B-type natriuretic peptide was greater in the infarct 
than in the noninfarct region even when left ventricular 
dysfunction was comparable. 
Because the amount of B-type natriuretic peptide secreted 
from the anterior ventricle is also significantly greater in the 
inferior infarction group than in control subjects, the increased 
secretion of the peptide from the infarct region cannot be 
explained solely by secretion from the viable cells within the 
infarct. Rather, the myocytes surrounding the infarct are likely 
to be the source of the increased secretion of B-type natriuretic 
peptide. Because secretion of the peptide from the anterior 
ventricle is greater in the anterior than in the inferior infarc- 
tion group, it appears that B-type natriuretic peptide secretion 
is augmented by the regional stretch, which is greatest around 
the infarct. 
In the anterior infarction group, there was no significant 
difference between the plasma B-type natriuretic peptide level 
in the anterior interventricular vein and the coronary sinus. 
This finding suggests hat in patients with myocardial infarction 
as in normal adult humans, B-type natriuretic peptide is 
secreted mainly from the ventricles and not from the atria. 
However, in the inferior myocardial infarction group, there 
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was a significant increase in the level of B-type natriuretic 
peptide between the anterior interventricular vein and coro- 
nary sinus. We believe that this increase is due to increased 
secretion of B-type natriuretic peptide from the inferior infarct 
region because the coronary sinus partly drains the inferior 
ventricle. This finding further supports our conclusion that 
B-type natriuretic peptide secretion is markedly greater in the 
area regionally stretched by myocardial infarction. 
In contrast, the slope of the regression line of A-type 
natriuretic peptide secretion from the anterior ventricle did 
not differ between the anterior and inferior infarction groups. 
This finding suggests that A-type natriuretic peptide secretion 
is less sensitive than B-type natriuretic peptide secretion to the 
regional ventricular stretch caused by myocardial infarction. 
Conclusions. 1) Significant secretion of A-type natriuretic 
peptide from the ventricles occurs in patients with old myo- 
cardial infarction but not in normal adult humans. 2) B-type 
natriuretic peptide is secreted mainly from the ventricles both 
in normal adult humans and in patients with old myocardial 
infarction. 3) Secretion of A-type and B-type natriuretic pep- 
tide from the ventricles increases in proportion to the severity 
of left ventricular dysfunction. 4) Secretion of B-type natri- 
uretic peptide is significantly greater from the infarct region 
than from the noninfarct region, whereas this not the case with 
A-type natriuretic peptide. These findings suggest that the 
regional ventricular wall stretch caused by myocardial infarc- 
tion strongly stimulates B-type natriuretic peptide secretion 
and that B-type natriuretic peptide is more sensitive than 
A-type natriuretic peptide as a marker of regional ventricular 
stretch. 
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